Evidence map›Paper›PMID 36881081›Full record

ArticleIn vivo (Athens, Greece)

HB Surface Antigen Level as a Useful Predictor for the Treatment Response to Tenofovir Alafenamide in Nucleoside Analogue Naïve Chronic Hepatitis B.

Masahiro Matsui, Akira Asai, Kosuke Ushiro, Keisuke Yokohama, Shinya Fukunishi, Soo Ki Kim, Hiroki Nishikawa

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Masahiro MatsuiThe Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Akira AsaiThe Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kosuke UshiroThe Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Keisuke YokohamaThe Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Shinya FukunishiThe Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Soo Ki KimDepartment of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
Hiroki NishikawaThe Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; nishikawa_6392_0207@yahoo.co.jp.
Osaka University of Pharmaceutical Sciences · JPKobe Asahi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo elucidate factors contributing to hepatitis B virus (HBV)-DNA clearance following tenofovir alafenamide (TAF) therapy in nucleoside analogue (NA) naïve patients with chronic hepatitis B (CHB) (n=92, 11 cirrhotic cases). PATIENTS AND

methodsThe time interval between the start of TAF therapy and first confirmed undetectable HBV-DNA after TAF therapy was calculated. Univariate and multivariate analyses of factors related to undetectable HBV-DNA after TAF therapy were performed.

resultsHB envelop antigen seropositivity was found in 12 patients (13.0%). The cumulative undetectable HBV-DNA rate at 1- and 2- year was 74.9% and 90.9%. In the multivariate Cox regression analysis of the undetectable HBV-DNA after TAF therapy, HBsAg level >1,000 IU/ml (p=0.0082, HBsAg level <100 IU/ml as a reference standard) was an independent predictor of the undetectable HBV-DNA after TAF therapy.

conclusionBaseline higher HBsAg level can be an adverse predictor for the undetectable HBV-DNA after TAF therapy in NA naïve CHB patients.

Indexed as

Antigens, SurfaceHepatitis B, ChronicDNA, ViralHepatitis B Surface AntigensHumansNucleosidesAntigens, SurfaceDNA, ViralHepatitis B Surface AntigensNucleosidesChronic hepatitis BHBsAgpredictorTenofovir alafenamide

Identifiers

PMID36881081
PMCPMC10026686
OpenAlexW4323347731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.